Isotopia Molecular Imaging has partnered with isotope technology firm Eckert & Ziegler for the development of its PSMA-11 kit for prostate cancer imaging.
The companies will finalize the development of Isotopia's gallium-68-HBED-CC-PSMA (gallium-68-PSMA-11) kit, which is used for the imaging and staging of prostate cancer.
The collaboration includes making the kit feasible on Eckert & Ziegler's KitLab, having its GalliaPharm in the drug master file of the kit, and completing the necessary steps to obtain marketing authorization in the European Union.
PSMA-11 is a small molecule that binds to prostate-specific membrane antigen (PSMA). When radiolabeled with gallium-68, it is a convenient, clinically efficient approach to imaging prostate cancer with PET, according to the company.